Please save/export the filled in form as PDF before submitting it to Ugeskrift for Læger or Danish Medical Journal.

Date: 4. februar 2021			
Your name: Rasmus O Bak			
Manuscript title: CRISPR/Cas geneditering af humane stamceller til kurativ behandling af primær			
Manuscript number (if known):			

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

Tim	e frame: Since the initial plar	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	Innovation Fund Denmark, Job Research Foundation, Novo Nordisk Foundation, and Carlsberg Foundation supported the PASCAL- MID project on CRISPR/Cas gene editing of stem cells from patients with primary immunodeficiency	

Click TAB in last row to add extra rows

2	Grants or contracts from	□ None			
	any entity (if not indicated	R.O.B. rapporterer			
	in item #1 above).	forskningsfinansiering			
		fra Novo Nordisk.			
3	Royalties or licenses	□ None			
		R.O.B. modtager			
		licensroyalties fra			
		patenter relateret til			
		CRISPR/Cas- genomredigering og			
		celleterapi.			
4	Consulting fees	None     Non			
5	Payment or honoraria for	None     Non			
	lectures, presentations,				
	speakers bureaus,				
	manuscript writing or educational events				
	educational events				
6	Payment for expert	⊠ None			
	testimony				
7	Support for attending	⊠ None			
	meetings and/or travel	Z None			
8	Patents planned, issued or	None			
0	pending	None			
	pending	R.O.B. er medopfinder af patenter relateret til			
		CRISPR/Cas-			
		genomredigering og			
		celleterapi.			
9	Participation on a Data	□ None			
	Safety Monitoring Board				
	or Advisory Board				
10	Leadership or fiduciary	⊠ None			
10	role in other board,	None			
	society, committee or				
	advocacy group, paid or				
	unpaid				
11	Stack or stack antions	□ None			
11	Stock or stock options	□ None  R O R or medstifter af			
11	Stock or stock options	R.O.B. er medstifter af			
11	Stock or stock options				

12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None     Non	
13	Other financial or non-	None     Non	
	financial interests		

Please place an "X" next to the following statement to indicate your agreement:

🛛 I certify that I have answered every question and have not altered the wording of any of the questions on this form.

## IMPORTANT for Ugeskrift for Læger & Danish Medical Journal

Please save/export the filled in form as PDF before submitting it to Ugeskrift for Læger or Danish Medical Journal.

Date:	2/12/2025
Your Name:	Mette Holm
Manuscript Title:	CRISPR geneditering af humane stamceller til kurativ behandling af primær immundefekt
Manuscript Number (if known):	Click or tap here to enter text.
• • • •	e ask you to disclose all relationships/activities/interests listed below that are related to the

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	Innovation Fund Denmark, Job Research Foundation, Novo Nordisk Foundation, and Carlsberg Foundation supported the PASCAL- MID project on CRISPR/Cas gene editing of stem cells from patients with primary immunodeficiency	Click the tab key to add additional rows.
		Time frame: past 36 month	s
2	Grants or contracts from any entity (if not indicated in item #1 above).	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	None	
4	Consulting fees	None None □	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	[⊠] None	
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None	
10	Leadership or fiduciary role in other board,	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	society, committee or advocacy group, paid or unpaid	Telationship of indicate none (add rows as needed)	made to you or to your institution;
11	Stock or stock options	[⊠] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	[⊠] None	
Plea [⊠]	Please place an "X" next to the following statement to indicate your agreement:  \[ \begin{align*} \Boxed{I} \text{ certify that I have answered every question and have not altered the wording of any of the questions on this form.} \]		

Date:	2/12/2025
Your Name:	Bjarne K. Møller
Manuscript Title:	[Innovation Fund Denmark, Job Research Foundation, Novo Nordisk Foundation, and Carlsberg Foundation supported the PASCALMID project on CRISPR/Cas gene editing of stem cells from patients with primary immunodeficiency
Manuscript Number (if known):	[Click or tap here to enter text.]

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	[☑] None  Time frame: past 36 month	Click the tab key to add additional rows.
2	Grants or contracts from any entity (if not indicated in item #1 above).	Beta Health®, Ministery for Interior and Health Denmark, Bloddonorerne Danmark	
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Danish Rheumatological Society, Medicinrådet	
6	Payment for expert testimony	Danish Medical Agency	
7	Support for attending meetings and/or travel	[⊠] None	
8	Patents planned, issued or pending	European patent PCT/EP2024/057786	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	European Blood Alliance, ScandiaTransplant, Life Science Denmark	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	Novo Nordisk	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	[□] None	
Please place an "X" next to the following statement to indicate your agreement:			
	I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Please save/export the filled in form as PDF before submitting it to Ugeskrift for Læger or Danish Medical Journal.

Date: 4. februar 2021		
Your name: Jacob Giehm Mikkelsen		
Manuscript title:	CRISPR/Cas geneditering af humane stamceller til kurativ behandling af primær	
Manuscript number (if known):		

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

Tim	e frame: Since the initial plar	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	Innovation Fund Denmark, Job Research Foundation, Novo Nordisk Foundation, and Carlsberg Foundation supported the PASCAL- MID project on CRISPR/Cas gene editing of stem cells from patients with primary immunodeficiency	

Click TAB in last row to add extra rows

2	Grants or contracts from	None
	any entity (if not indicated	
	in item #1 above).	
-		
3	Royalties or licenses	None
4	Consulting fees	None     Non
5	Payment or honoraria for	None     Non
	lectures, presentations,	
	speakers bureaus,	
	manuscript writing or	
	educational events	
,	B 15	
6	Payment for expert	None     Non
	testimony	
7	Compart for attanding	₩ N
7	Support for attending	⊠ None
	meetings and/or travel	
8	Patents planned, issued or	⊠ None
O	pending	Notice
	perianig	
9	Participation on a Data	□ None
	Safety Monitoring Board	J.G.M. er medlem af
	or Advisory Board	scientific advisory board
	Ş	hos nChromaBio
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or	None     Non
	unpaid	
	apaa.	
11	·	
11	Stock or stock options	None
11	·	None
	·	⊠ None
	Stock or stock options	
12	Stock or stock options  Receipt of equipment,	None None
	Stock or stock options  Receipt of equipment, materials, drugs, medical	
	Stock or stock options  Receipt of equipment, materials, drugs, medical writing, gifts or other	
	Stock or stock options  Receipt of equipment, materials, drugs, medical	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None □
	Receipt of equipment, materials, drugs, medical writing, gifts or other services  Other financial or non-	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None □

Please place an "X" next to the following statement to indicate your agreement:

 $\boxtimes$  I certify that I have answered every question and have not altered the wording of any of the questions on this form.

### IMPORTANT for Ugeskrift for Læger & Danish Medical Journal

Please save/export the filled in form as PDF before submitting it to Ugeskrift for Læger or Danish Medical Journal.

Dat	te:	2/12/2025			
You	Name: Trine Mogensen				
Manuscript Title:		CRISPR geneditering af humane stamce immundefekt	CRISPR geneditering af humane stamceller til kurativ behandling af primær immundefekt		
Ma	nuscript Number (if kr	nown): Click or tap here to enter text.	Click or tap here to enter text.		
cor affe ind The epi tha	In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.  The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.  In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.				
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
	Time frame: Since the initial planning of the work				
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing,	Innovation Fund Denmark, Job Research Foundation, Novo Nordisk Foundation, and Carlsberg			

Grants or contracts from any entity (if not indicated in item

#1 above).

article processing charges, etc.)

No time limit for

this item.

MID project on CRISPR/Cas gene editing of stem cells from patients with primary immunodeficiency Click the tab key to add additional rows. Time frame: past 36 months None

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	None	
4	Consulting fees	None None □	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	[⊠] None	
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None	
10	Leadership or fiduciary role in other board,	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	[⊠] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	[⊠] None	
Plea 🖂	Please place an "X" next to the following statement to indicate your agreement:    I certify that I have answered every question and have not altered the wording of any of the questions on this form.		